Ensuring that a preservative system controls microbial contamination is a critical regulatory requirement for pharmaceutical and cosmetic manufacturers to ensure product safety and compliance. At NJ Labs, we provide USP <51> antimicrobial effectiveness testing (AET), also known as preservative efficacy testing. This test ensures that preservatives in your non-sterile products perform effectively throughout their shelf life, safeguarding both product integrity and consumer health.
As an FDA and DEA-registered laboratory, NJ Labs delivers accurate, reproducible microbiological testing results supported by experienced microbiology specialists and validated test methods. Our team performs USP 51 challenge studies, method suitability testing, and preservative system evaluations to help manufacturers meet compendial requirements and satisfy regulatory agencies.
USP <51> antimicrobial effectiveness testing ensures preservatives in your formulation prevent microbial growth under real-world use and storage conditions.
The test is required for multi-dose products and aqueous formulations that may be exposed to microbial contamination during manufacturing, distribution, or consumer use. Water and organic substances in formulations provide ideal environments for microbial growth, which makes preservative efficacy testing essential. The examples of product categories, include injectables, topical preparations, oral liquids, and cosmetics.
USP 51 preservative efficacy testing confirms that a formulation’s preservative system will:
Preservatives are incorporated into many pharmaceutical and cosmetic formulations to inhibit the growth of bacteria, yeast, and mold, but their effectiveness depends on concentration, formulation chemistry, pH, and compatibility with other ingredients. Without validated preservative efficacy testing, manufacturers cannot be certain that their preservative system will perform reliably in the final product.
USP <51> antimicrobial effectiveness testing helps manufacturers:
NJ Labs performs the full scope of USP <51> testing services including:
Before validating a preservative challenge study, it’s essential to confirm that the test method can accurately recover the challenge organisms despite the product and its preservative system. This process is known as method suitability testing.
Certain preservatives or formulation components can interfere with microbial recovery during plate counting, leading to artificially low microbial counts and a misleading assessment of preservative efficacy. NJ Labs performs method suitability testing to identify and neutralize any such interference, ensuring that challenge study results accurately reflect true antimicrobial performance.
USP <51> testing requires exposure to five standardized challenge microorganisms, each representing a major category of microbial contamination risk:
To ensure accurate microbial recovery and valid test results:
NJ Labs conducts USP <51> antimicrobial effectiveness testing according to the United States Pharmacopeia guidelines using a validated challenge study protocol.
Each product sample is inoculated with a standardized concentration of the five USP-specified challenge organisms, ensuring consistency across samples. The inocula are prepared at specific colony-forming units (CFU) per milliliter to ensure consistent and reproducible conditions during testing.
Inoculated samples are incubated under controlled temperature conditions, typically at 20-25°C, and analyzed at the defined time intervals specified by USP <51>:
Microbial populations are counted at each time point using validated plate count methods, ensuring accurate measurement of microbial growth and reduction. The results are compared against the USP <51> acceptance criteria for the applicable product category, which include log reduction requirements for bacteria and the absence of fungal growth.
See the USP <51> acceptance criteria table in the Product Categories section below.
USP <51> defines four product categories, each with specific antimicrobial performance requirements. The applicable category is determined by the product type and route of administration.
Category 1 includes products that require the highest level of microbial protection. These products present the greatest patient safety risk from microbial contamination, so they must meet the most stringent acceptance criteria.
Examples: Injectable drug products, ophthalmic solutions, ophthalmic drops
Category 2 includes topical non-sterile and non-aqueous products, which are applied to skin or mucosal surfaces. These products are evaluated against moderate antimicrobial performance criteria.
Examples: Topical creams, lotions, ointments, nasal sprays, ear drops
Category 3 includes aqueous oral formulations that require protection from microbial contamination throughout their shelf life.
Examples: Oral solutions, oral suspensions, liquid dietary supplements
Category 4 criteria are similar to those of Category 3 for bacterial and fungal assessment but take into account the unique formulation characteristics of antacid products. Due to the pH constraints of antacid formulations, which limit compatible preservatives, testing is crucial to confirm their antimicrobial effectiveness.
Examples: Aqueous antacid suspensions, antacid liquids
The following summary outlines the USP <51> compendial acceptance criteria for each product category, focusing on bacterial log reduction and absence of fungal growth over defined time intervals.
| Category | Product Type | Bacteria (Log Reduction) | Yeast & Mold (Log Reduction) | No Increase After |
|---|---|---|---|---|
| 1 | Parenteral / Ophthalmic | ≥2 log by Day 2; ≥3 log by Day 7 | No increase from Day 14 to Day 28 | Day 14 |
| 2 | Topical / Non-sterile Aqueous | ≥2 log by Day 14 | No increase from Day 14 to Day 28 | Day 14 |
| 3 | Oral Aqueous | No increase from initial Day 14 to Day 28 | No increase from initial Day 14 to Day 28 | Day 14 |
| 4 | Antacid Formulations | No increase from initial Day 14 to Day 28 | No increase from initial Day 14 to Day 28 | Day 14 |
USP <51> antimicrobial effectiveness testing is commonly required or recommended for the following product types:
International note: Manufacturers targeting EU or other international markets may also require testing under ISO 11930 (cosmetics) or EP 5.1.3 (European Pharmacopoeia). Contact NJ Labs to discuss cross-market compliance testing options
NJ Labs can also perform USP <51> challenge studies on R&D-stage formulations at multiple preservative concentrations within the same study design. This approach generates comparative antimicrobial performance data across a defined concentration range, enabling formulators to identify the minimum effective preservative level that meets the USP <51> acceptance criteria for their target product category.
The data from these studies supports evidence-based decisions on preservative selection and concentration during formulation development – reducing the risk of late-stage reformulation and providing a documented rationale for the final preservative system used in regulatory submissions. This service is available for both new product development and reformulation projects where existing preservative systems are being reviewed or optimized.
NJ Labs combines accredited laboratory infrastructure with extensive microbiological expertise and a client-focused approach to ensure efficient project management.
NJ Labs provides USP <51> antimicrobial effectiveness testing, preservative challenge studies, and method suitability testing, tailored to the specific needs of pharmaceutical, cosmetic, and personal care product manufacturers.
We also support R&D teams conducting preservative concentration optimization studies – generating comparative USP <51> data across multiple preservative levels to identify the optimal system for your formulation before final product lock.
To initiate a project, it is helpful to have the following information ready: product type and category, dosage form, approximate viscosity, target market(s), and any timeline or regulatory deadline constraints.
Contact our laboratory team today. We typically respond to testing inquiries within one business day and can provide a customized project scope and quote based on your specific requirements. Rest assured, all project discussions are held in strict confidence.
USP <51> testing determines whether the preservative system in a non-sterile product can effectively prevent microbial growth under controlled conditions that simulate real-world use. Results are then compared to the compendial acceptance criteria, which vary based on the product category.
